AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2815968
Drug: Suckling mouse
RxNorm normalized name: house mouse skin extract
DrugBank: Mus musculus skin (DB10412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suckling mouse brain rabies vaccine with equine hyperimmune serum (40 IU per kg body weight)
Trial: 2815968
Drug: Suckling mouse
RxNorm normalized name: house mouse skin extract
DrugBank: Mus musculus skin (DB10412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suckling mouse brain rabies vaccine without equine hyperimmune serum
Trial: 25939894
Drug: Cilengitide 2000
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide 2000 mg 1×/week i.v. (CIL-once)
Trial: 25939894
Drug: Control (cetuximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (cetuximab plus platinum-based chemotherapy)
Trial: 18593517
Drug: Valsartan/HCTZ (160/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/HCTZ (160/12.5 mg, titrated to 160/25 mg after 2 weeks and to 320/25 mg after 4 weeks)
Trial: 18593517
Drug: Valsartan monotherapy
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan monotherapy (160 mg, titrated to 320 mg after 2 weeks and sham-titrated to 320 mg after 4 weeks)
Trial: 16295261
Drug: Participation in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participation in research aimed at determining treatment effectiveness
Trial: 16295261
Drug: Established treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established treatments
Trial: 12232450
Drug: Noncorticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncorticosteroid treatment (control group)
Trial: 10406361
Drug: Behavioural intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioural intervention by an old-age psychiatry hospital outreach team, including seminars and weekly visits from a psychiatric nurse over 6 months.
Trial: 1979494
Drug: Drug A
RxNorm normalized name: Drug additive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug A (propyphenazone 250 mg, ethylmorphine 5 mg, caffeine 5 mg)
Trial: 1979494
Drug: Drug B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug B (dipyrone 500 mg, diphenhydramine 12.5 mg, adiphenine 5 mg, ethyl aminobenzoate 2.5 mg)
Trial: 375943
Drug: 1-phenylephrine hydrochloride
RxNorm normalized name: chlorpheniramine
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-phenylephrine hydrochloride gel
Trial: 15757015
Drug: Alendronate 5
RxNorm normalized name: ALENDRONATE 5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 5 mg/d for 2 years and 10 mg/d thereafter
Trial: 12618160
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (2 mg 17beta‐oestradiol and 1 mg norethisterone acetate)
Trial: 9350383
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral zolmitriptan
Trial: 9350383
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral ergotamine
Trial: 9350383
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of zolmitriptan and ergotamine
Trial: 29717288
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 5 mg
Trial: 29717288
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 5 mg plus dexmedetomidine 5 µg intrathecally
Trial: 18514303
Drug: gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine plus axitinib (1000 mg/m² plus 5 mg twice daily)
Trial: 18514303
Drug: gemcitabine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine alone (1000 mg/m²)
Trial: 11800503
Drug: Amisulpride 50
RxNorm normalized name: amisulpride 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride 50 mg o.d.
Trial: 11800503
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg o.d.
Trial: 8645650
Drug: Goserelin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin treatment in women with adenomyosis
Trial: 31648967
Drug: DWI+FLAIR sequences
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWI+FLAIR sequences in combination
Trial: 27622611
Drug: Desmopressin 0.2
RxNorm normalized name: DESMOPRESSIN 0.2MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.2 mg
Trial: 11696804
Drug: Desmopressin 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.4 mg
Trial: 11696804
Drug: Desmopressin 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.6 mg
Trial: 7953039
Drug: Family-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based intervention including monthly 45-minute counselling sessions focused on management of social and occupational problems, medication management, family education, family group meetings, and crisis intervention.
Trial: 3069568
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g i.v. Cefotetan
Trial: 27032449
Drug: Internet-based problem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based problem solving therapy with weekly student support (n=136)
Trial: 27032449
Drug: Internet-based problem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based problem solving therapy (n=136)
Trial: 24173623
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg to a maximum of 200 mg/day
Trial: 24173623
Drug: Sertraline (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (in subset meeting DSM-IV criteria)
Trial: 23690416
Drug: Experimental arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental arm (chemotherapy based on ERCC1 and RRM1 levels)
Trial: 20569705
Drug: Carperitide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carperitide treatment (69.4%)
Trial: 20569705
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blockers (53.9%)
Trial: 20453720
Drug: Partner-delivered therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partner-delivered therapy (PDPT)
Trial: 16274808
Drug: Tinnitus retraining
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinnitus retraining therapy (TRT)
Trial: 9875635
Drug: E2 antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 antibodies presence
Trial: 7979464
Drug: Dexamethasone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.2 mg/kg three times a day for two weeks)
Trial: 22789766
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (FF/VI) 50/25 μg, 100/25 μg, and 200/25 μg, dosed once daily in the morning for 28 days
Trial: 18534970
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (L3-4)
Trial: 15831640
Drug: glipizide 5
RxNorm normalized name: glipizide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glipizide 5 mg/day
Trial: 15831640
Drug: metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 500 mg/day
Trial: 12182254
Drug: Piperacillin 12
RxNorm normalized name: PIPERACILLIN 12/TAZOBACTAM 1.5GM/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 12 g/tazobactam 1.5 g continuous infusion over 24 hours
Trial: 12182254
Drug: Piperacillin 6
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin 6 g/tazobactam 0.75 g continuous infusion over 24 hours
Trial: 12182254
Drug: Piperacillin 3
RxNorm normalized name: piperacillin 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 3 g/tazobactam 0.375 g q6h for 24 hours
Trial: 12182254
Drug: Piperacillin 6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 6.75 g continuous infusion over 24 hours
Trial: 10564834
Drug: PFD formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFD formulation
Trial: 10564834
Drug: Saline formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline formulation
Trial: 6777131
Drug: Metoclopramide (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (administered orally in a double-blind fashion)
Trial: 31253407
Drug: Iron-fortified formula
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified formula (12 mg/L)
Trial: 30239384
Drug: Lorazepam in
RxNorm normalized name: Lorazepam Intensol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam in combination with haloperidol
Trial: 30239384
Drug: Benzodiazepines (scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines (scheduled doses or continuous infusion)
Trial: 20048189
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with cisplatin and fluorouracil
Trial: 18067659
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus antidepressants (UCandAD)
Trial: 16279567
Drug: 0.1% olopatadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% olopatadine hydrochloride ophthalmic solution, administered twice daily for 2 weeks in addition to nasal or systemic antiallergy medication.
Trial: 16279567
Drug: No ocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ocular therapy (control group), using only previously prescribed antiallergy medication for 2 weeks.
Trial: 8061848
Drug: Spirapril 3
RxNorm normalized name: spirapril 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril 3 mg once daily
Trial: 3141101
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml of a fermented milk test product supplying at least 2 X 10(9) live Lactobacillus acidophilus bacteria daily and 6.5% lactulose as substrate for the bacteria.
Trial: 28279492
Drug: COX-1 inhibitor
RxNorm normalized name: COX-1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX-1 inhibitor reactions
Trial: 25289793
Drug: Nitrate gels
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate gels (NIT) + UV‐A
Trial: 22520278
Drug: Oral cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabis brief intervention (C-O)
Trial: 22520278
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health brief intervention (H-O)
Trial: 15517844
Drug: Sertraline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline and clonazepam
Trial: 15517844
Drug: Sertraline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline and placebo
Trial: 8441108
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered theophylline (aminophylline)
Trial: 2874906
Drug: GRF 1-29
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRF 1-29 (1 microgram/kg i.v.) with pirenzepine (0.6 mg/kg, i.v.)
Trial: 2874906
Drug: TRH (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH (200 micrograms/kg, i.v.) with pirenzepine (0.6 mg/kg, i.v.)
Trial: 29427527
Drug: Oral antioxidants
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antioxidants (vitamins C and E and α‐lipoic acid)
Trial: 27861342
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical therapy (diet and exercise counseling)
Trial: 22615190
Drug: cilostazol plus
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cilostazol plus l-carnitine 1 g twice-daily
Trial: 17702897
Drug: Eculizumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab treatment in antithrombotic-treated patients (n = 103)
Trial: 10496251
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose 1.1 mg/d)
Trial: 10496251
Drug: Haloperidol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (mean dose 1.2 mg/d)
Trial: 9185259
Drug: Intramuscular anti-snake
RxNorm normalized name: North American coral snake antivenin
DrugBank: Coral snake (micrurus fulvius) immune globulin antivenin (equine) (DB13883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular anti-snake venom administration as a first aid measure
Trial: 1684197
Drug: Parenterally-administered cephalosporin
RxNorm normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenterally-administered cephalosporin
Trial: 24272966
Drug: D-ribose (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-ribose (all doses)
Trial: 18078723
Drug: Intranasal methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal methamphetamine 25 mg
Trial: 18078723
Drug: Intranasal methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal methamphetamine 50 mg
Trial: 18078723
Drug: Intranasal methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal methamphetamine 0 mg (control)
Trial: 11239552
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate (3.6 mg depot) every 28 days for 8 weeks
Trial: 11239552
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate (3.6 mg depot)
Trial: 9727569
Drug: Immediate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate therapy (group A: ritonavir, zidovudine and lamivudine)
Trial: 9727569
Drug: Delayed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed therapy (group B: ritonavir supplemented by zidovudine and lamivudine on day 21)
Trial: 7958383
Drug: Procaine penicillin
RxNorm normalized name: procaine penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine penicillin G (4.8 mega units, intramuscularly), oral probenecid (1 g), and clavulanate-potentiated amoxycillin (375 mg tablet, orally)
Trial: 16180594
Drug: Continuous passive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous passive motion (CPM) treatment
Trial: 27002662
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (CPT) including active stretching, ROM and pendulum exercises
Trial: 25487477
Drug: Single shot
RxNorm normalized name: ACL7 SINGLE SHOT EPIDURAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single shot bilateral intercostal block with levobupivacaine (L group)
Trial: 19816834
Drug: Narrative exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative exposure therapy (NET)
Trial: 12236631
Drug: Tianeptine (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine (37.5 mg)
Trial: 10438552
Drug: Spinal cord
RxNorm normalized name: BOS TAURUS SPINAL CORD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal cord stimulation (SCS) plus standard medical treatment
Trial: 20586748
Drug: Intracapsular local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracapsular local anaesthesia with 20 ml ropivacaine 0.5%
Trial: 20586748
Drug: Intra-articular local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular local anaesthesia with 20 ml ropivacaine 0.5%
Trial: 16321179
Drug: All types
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All types of reperfusion therapy
Trial: 11904788
Drug: Ondansetron 24
RxNorm normalized name: ondansetron 24 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 24 mg once daily
Trial: 2047061
Drug: Intravaginal prostaglandin
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal prostaglandin E2 (PGE2) gel (2.0 mg, twice-weekly)
Trial: 6996112
Drug: No iron
RxNorm normalized name: No Iron Multivitamin with Minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No iron or intermittent iron supplement
Trial: 30690141
Drug: Paclitaxel drug-coated
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel drug-coated balloon (DCB)
Trial: 27214300
Drug: Lanreotide depot/autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide depot/autogel 120 mg
Trial: 27762088
Drug: BBT plus
RxNorm normalized name: BBT-059
DrugBank: BBT-059 (DB18142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBT plus 50 mg ipragliflozin
Trial: 27762088
Drug: BBT plus
RxNorm normalized name: BBT-059
DrugBank: BBT-059 (DB18142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBT plus 50 mg ipragliflozin and 20 mg teneligliptin
Trial: 22844543
Drug: Liquefied carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquefied carbohydrate (CL, peach blended in 500 ml water + 250 ml water)
Trial: 22844543
Drug: Solid carbohydrate
RxNorm normalized name: Corydalis solida whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid carbohydrate (CS, whole peaches + 750 ml water)
Trial: 19232755
Drug: Amlodipine-based treatment
RxNorm normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine-based treatment and atorvastatin 10 mg
Trial: 15272513
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml ropivacaine 7.5 mg/ml
Trial: 15272513
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml ropivacaine 7.5 mg/ml
Trial: 15272513
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml ropivacaine 7.5 mg/ml (nerve block)
Trial: 15272513
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml ropivacaine 7.5 mg/ml (nerve block)
Trial: 9652426
Drug: Zidovudine, 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine, 1000 mg daily for 24 weeks
Trial: 1443451
Drug: Astemizole, one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole, one 10-mg tablet each morning for 4 weeks
Trial: 2935051
Drug: Cimetidine, 300
RxNorm normalized name: Cimetidine, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 300 mg every 6 hr
Trial: 2935051
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg every 12 hr
Trial: 2935051
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no other treatment)
Trial: 29228392
Drug: Ombitasvir/paritaprevir/ritonavir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombitasvir/paritaprevir/ritonavir plus dasabuvir with no RBV for the first 2 weeks followed by weight-based dosing thereafter (Arm A)
Trial: 29228392
Drug: Ombitasvir/paritaprevir/ritonavir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombitasvir/paritaprevir/ritonavir plus dasabuvir with low-dose RBV (600 mg) once daily for all 12 weeks (Arm C)
Trial: 16297747
Drug: 1‐ to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐ to 1.5‐microg/kg dose of fentanyl
Trial: 11977539
Drug: CGS 20267
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 20267 0.5 mg once daily
Trial: 11977539
Drug: CGS 20267
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 20267 1.0 mg once daily
Trial: 2406330
Drug: Calcitonin (415
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin (415 pmol i.v. bolus injection followed by a 90‐min infusion to reach an overall dose of 62.25 pmol/kg body mass)
Trial: 6988522
Drug: Gentamicin (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (normal or subnormal doses)
Trial: 23348146
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg bid
Trial: 19057212
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX‐A) injection into the prostate
Trial: 17724497
Drug: Dalbavancin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalbavancin (1 g followed by 500 mg one week later)